Nexell Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Cell therapy company completes a $63 mil. private placement with institutional investors. Irvine, California-based Nexell will use the proceeds to retire about $34 mil. in convertible subordinated debentures held by shareholder Baxter, as well as for "general corporate purposes." Nexell's Isolex 300i gained FDA approval in July for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood grafts used to restore cancer patients' immune and blood-forming systems following high dose chemotherapy (1"The Gray Sheet" July 12, p. 11). Lehman Brothers served as placement agent for the transaction
You may also be interested in...
Nexell Planning To Seek Labeling Expansion For Isolex 300i In 2001
Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.